skip to content

Department of Oncology


Emma Beddowes

Dr Emma Beddowes



Graduate Students

Please contact Dr Beddowes for further information.

Research Interests

Dr Beddowes is a medical oncologist with a special interest in breast cancer and the use of molecular biomarkers to characterise tumour evolution following treatment. It is known that patients with cancer shed tumour DNA into their bloodstream and my particular interest is in using this circulating tumour DNA (ctDNA) to track tumour evolution in patients with advanced breast cancer. I am the principle investigator of the DETECT trial which enrols patients into a programme of serial blood samples whilst undergoing chemotherapy and other treatments. Previous work in our group has shown that changes in ctDNA often proceed those seen on standard imaging and it is my aim to establish the clinical utility of this technique for both monitoring purposes and also for determining potential pathways of resistance to treatment


Pubmed journal articles - pubmed

Key publications

Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA. Gao M†, Callari M†, Beddowes E, Sammut S-J, Grzelak M, Biggs H, Jones L, Boumertit A, Linn SC, Cortes J, Oliveira M, Baird R, Chin S-F, and Caldas C. Genome Medicine2019, 11:1. (†Contributed equally).

Predicting treatment resistance and relapse through circulating DNA. Beddowes E, Sammut SJ, Gao M, Caldas C. Breast. 2017 Aug;34 Suppl 1:S31-S35. doi: 10.1016/j.breast.2017.06.024. Epub 2017 Jul 8. DOI:10.1016/j.breast.2017.06.024.

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers. Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, Repana D, Steele JP, Schmid P, Szyszko T, Cook G, Diaz M, Feng X, Johnston A, Thomson J, Sheaff M, Wu BW, Bomalaski J, Pacey S, Szlosarek PW. J Clin Oncol. 2017 Jun 1;35(16):1778-1785. doi: 10.1200/JCO.2016.71.3230. Epub 2017 Apr 7. DOI: 10.1200/JCO.2016.71.3230:

POSEIDON trial phase 1b results: Safety and preliminary efficacy of the isoform selective PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC) patients (pts) - including response monitoring by plasma circulating tumor (ct) DNA. Baird RD, Van Rossum A, Oliveira M, Beelen K, Garcia-Corbacho J, Mandjes IAM, Vallier A-L, van Werkhoven ED, Kumar SS, van Tinteren H, Beddowes E, Rosing H, Schrier M, de Vries Schultink A, Saura C, Bernards R, Tabernero J, Cortes J, Caldas C, Linn SC. Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2520-2520.  Published online May 11, 2017. DOI:10.1200/JCO.2016.34.15_suppl.2520

Characterising the use and impact of bisphosphonates in patients with bone metastases from non-small cell lung cancer; a single centre experience. Beddowes EJ, Hatipoglu E, Montes, A, Spicer, J, Moller H, Lal, R. Lung Cancer 83, S6-S7. DOI 10.1016/S0169-5002(14)70017-0. January 2014.